Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: Implications for the tailored use of anthracycline-based chemotherapies

Histopathology

Volumn 60, Issue 3, 2012, Pages 482-488

  Brunello, Eleonora ^a   Brunelli, Matteo ^a   Manfrin, Erminia ^a   Nottegar, Alessia ^a   Bersani, Samantha ^a   Vergine, Marco ^a   Molino, Annamaria ^b   Fiorio, Elena ^b   Chilosi, Marco ^a   Gobbo, Stefano ^a   Martignoni, Guido ^a   Bonetti, Franco ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

Author keywords

Her2 neu; In situ hybridization; Lobular breast carcinoma; Topoisomerase II

Indexed keywords

ANTHRACYCLINE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIDERMAL GROWTH FACTOR RECEPTOR 2; TOPOISOMERASE II ALPHA; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CHROMOGENIC IN SITU HYBRIDIZATION; CLINICAL ARTICLE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; LOBULAR BREAST CANCER; LOBULAR BREAST CARCINOMA; METASTASIS; PHARMACOGENETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SILVER IN SITU HYBRIDIZATION;

ANTHRACYCLINES; ANTIGENS, NEOPLASM; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA, LOBULAR; CHEMOTHERAPY, ADJUVANT; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; DNA-BINDING PROTEINS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INDIVIDUALIZED MEDICINE; RECEPTOR, ERBB-2;

EID: 84856275164     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.04067.x     Document Type: Article

References (26)

1. Pritchard KI. Are HER2 and TOP2A useful as prognostic or predictive biomarkers for anthracycline-based adjuvant chemotherapy for breast cancer? J. Clin. Oncol. 2009; 27; 3875-3876.
2. O'Malley FP, Chia S, Tu D et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J. Natl Cancer Inst. 2009; 101; 644-650.
3. Pritchard KI. Optimizing the delivery of targeted research: an opportunity for comparative effectiveness research. J. Clin. Oncol. 2010; 28; 1089-1091.
4. Pritchard KI, Messersmith H, Elavathil L, Trudeau M, O'Malley F, Dhesy-Thind B. HER-2 and topoisomerase II as predictors of response to chemotherapy. J. Clin. Oncol. 2008; 26; 736-744.
5. Tanner M, Isola J, Wiklund T et al. Topoisomerase IIalpha gene amplification predicts favorable treatment response to tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2/neu-amplified breast cancer: Scandinavian Breast Group Trial 9401. J. Clin. Oncol. 2006; 24; 2428-2436.
6. Jarvinen TA, Tanner M, Rantanen V et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am. J. Pathol. 2000; 156; 839-847.
7. Harris LN, Broadwater G, Abu-Khalaf M et al. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. J. Clin. Oncol. 2009; 27; 3430-3436.
8. Petit T, Wilt M, Velten M et al. Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur. J. Cancer 2004; 40; 205-211.
9. Press MF, Sauter G, Bernstein L et al. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin. Cancer Res. 2005; 11; 6598-6607.
10. Knoop AS, Knudsen H, Balslev E et al. Retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J. Clin. Oncol. 2005; 23; 7483-7490.
11. Park K, Kim J, Lim S, Han S, Lee JY. Comparing fluorescence in situ hybridization and chromogenic in situ hybridization methods to determine the HER2/neu status in primary breast carcinoma using tissue microarray. Mod. Pathol. 2003; 16; 937-943.
12. Cristofanilli M, Gonzalez-Angulo A, Sneige N et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J. Clin. Oncol. 2005; 23; 41-48.
13. Pritchard KI. Tailored targeted therapy for all: a realistic and worthwhile objective against. Breast Cancer Res. 2009; 11(Suppl. 3); S8.
14. Wolff AC, Hammond ME, Schwartz JN et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J. Clin. Oncol. 2007; 25; 118-145.
15. Brunelli M, Manfrin E, Martignoni G et al. HER-2/neu assessment in breast cancer using the original FDA and new ASCO/CAP guideline recommendations: Impact on selecting patients for herceptin therapy. Am. J. Clin. Pathol. 2008; 129; 907-911.
16. Lal P, Salazar PA, Hudis CA, Ladanyi M, Chen B. HER-2 testing in breast cancer using immunohistochemical analysis and fluorescence in situ hybridization: a single-institution experience of 2, 279 cases and comparison of dual-color and single-color scoring. Am. J. Clin. Pathol. 2004; 121; 631-636.
17. Oakman C, Pestrin M, Cantisani E et al. Adjuvant chemotherapy - the dark side of clinical trials. Have we learnt more? Breast 2009; 18(Suppl. 3); S18-S24.
18. Oakman C, Moretti E, Galardi F, Santarpia L, Di Leo A. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Cancer Treat. Rev. 2009; 35; 662-667.
19. Coon JS, Marcus E, Gupta-Burt S et al. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer. Clin. Cancer Res. 2002; 8; 1061-1067.
20. Di Leo A, Gancberg D, Larsimont D et al. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 2002; 8; 1107-1116.
21. Vergine M, Brunelli M, Martignoni G et al. Suitability of infiltrative lobular breast carcinoma for anti-human epidermal growth factor receptor 2 treatment after the ASCO/CAP and 2009 St Gallen International Expert Consensus meeting. Histopathology 2010; 57; 935-940.
22. Tanner M, Jarvinen P, Isola J. Amplification of HER-2/neu and topoisomerase IIalpha in primary and metastatic breast cancer. Cancer Res. 2001; 61; 5345-5348.
23. Durbecq V, Desmed C, Paesmans M et al. Correlation between topoisomerase-IIalpha gene amplification and protein expression in HER-2 amplified breast cancer. Int. J. Oncol. 2004; 25; 1473-1479.
24. Cardoso F, Di Leo A, Larsimont D et al. Evaluation of HER2, p53, bcl-2, topoisomerase II-alpha, heat shock proteins 27 and 70 in primary breast cancer and metastatic ipsilateral axillary lymph nodes. Ann. Oncol. 2001; 12; 615-620.
25. Munro AF, Cameron DA, Bartlett JM. Targeting anthracyclines in early breast cancer: new candidate predictive biomarkers emerge. Oncogene 2010; 29; 5231-5240.
26. Bartlett JM, Munro AF, Dunn JA et al. Predictive markers of anthracycline benefit: a prospectively planned analysis of the UK National Epirubicin Adjuvant Trial (NEAT/BR9601). Lancet Oncol. 2010; 11; 266-274.